Impressive Results With Fingolimod in Pediatric MS Impressive Results With Fingolimod in Pediatric MS
In the first randomized trial in pediatric multiple sclerosis, fingolimod was associated with sizable reductions in relapse rate, new MRI lesions, brain atrophy, and disability progression compared with interferon beta.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Oral Drug Beats Interferon in First Pediatric MS Trial
(MedPage Today) -- Fingolimod cut relapses, brain shrinkage but with more adverse events (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - October 29, 2017 Category: General Medicine Source Type: news
Cardiac Effects of Fingolimod in MS Reversible Cardiac Effects of Fingolimod in MS Reversible
Fingolimod, used to treat multiple sclerosis, dampens cardiac autonomic modulation at rest and during challenges, but this effect appears to be reversible after discontinuation of the drug, a study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Pharma ’s social contract: time for everyone to join in
When a scandal occurs in pharma, the whole industry is tarred by the same brush. We ’re still suffering the ill effects of Martin Shkreli’s 5000%overnight price increase of a life-saving anti-parastic, from way back in 2015.Pharma ’s trust problemBrent Saunders, Chairman& CEO of Allergan,sees this as part and parcel of doing business in this industry. Pricing will always be controversial within healthcare, because choosing between two sets of health outcomes is fundamentally different from choosing between two different brands of an electric toaster. The problem is: this reality isn ’t widely acknowledged acro...
Source: EyeForPharma - September 6, 2017 Category: Pharmaceuticals Authors: Paul Simms Source Type: news
Pharma ’s social contract: time for everyone to join in
When a scandal occurs in pharma, the whole industry is tarred by the same brush. We ’re still suffering the ill effects of Martin Shkreli’s 5000%overnight price increase of a life-saving anti-parastic, from way back in 2015.Pharma ’s trust problemBrent Saunders, Chairman& CEO of Allergan,sees this as part and parcel of doing business in this industry. Pricing will always be controversial within healthcare, because choosing between two sets of health outcomes is fundamentally different from choosing between two different brands of an electric toaster. The problem is: this reality isn ’t widely acknowledged acro...
Source: EyeForPharma - September 6, 2017 Category: Pharmaceuticals Authors: Paul Simms Source Type: news
MS Drug Works in Kids
(MedPage Today) -- Top-line results suggest good safety profile for fingolimod in pediatric MS (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 5, 2017 Category: Neurology Source Type: news
Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded.
Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma.
The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledronic acid...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news
Fingolimod during pregnancy: Is it safe?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - June 7, 2017 Category: Consumer Health News Source Type: news
Multiple Sclerosis Drug Effectively Stops Mesothelioma Cells
Research from the University of Hawaii Cancer Center shows an immune suppression drug already used to treat multiple sclerosis could become an effective tool against malignant mesothelioma.
The drug, fingolimod (FTY720), showed an ability to shrink mesothelioma tumors cells in the laboratory and in animal models without causing substantial side effects.
Fingolimod, which is derived from the fungus isaria sinclairii, also is being studied for potential use with cervical, breast, lung and prostate cancers. This was the first study of its effectiveness with mesothelioma.
The Journal of Translational Medicine published the res...
Source: Asbestos and Mesothelioma News - May 11, 2017 Category: Environmental Health Authors: Matt Mauney Tags: anti-cancer effect on mesothelioma cells Dr. Haining Yang fingolimod mesothelioma FTY720 immune suppression drugs isaria sinclairii Journal of Translational Medicine mesothelioma life expectancy multiple sclerosis drugs Repurposing drugs Source Type: news
Novartis real-world data at AAN confirms benefit of Gilenya ® on four key measures of disease activity in relapsing MS
Novartis today announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya® (fingolimod) in the real-world setting, supporting previous findings from Phase III trials[1],[2]. (Source: World Pharma News)
Source: World Pharma News - April 24, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Glenmark gets tentative nod from USFDA for Fingolimod capsules
"Glenmark Pharmaceuticals USA has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 20, 2017 Category: Pharmaceuticals Source Type: news
Study sheds light on the biology of progressive form of multiple sclerosis
(Brigham and Women's Hospital) A research team led by scientists from Brigham and Women's Hospital has revealed how an FDA-approved drug works in the central nervous system in mice to suppress chronic inflammation. The drug, known as FTY720 (or Fingolimod) interferes with signals sent through sphingosine-1-phosphate receptors, and appears to reduce the pathogenic activities of astrocytes. The findings suggest the treatment may hold promise for a progressive and difficult-to-treat form of multiple sclerosis (MS) known as secondary progressive MS (SPMS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2017 Category: Global & Universal Source Type: news
How to empower your health and wellness customers
Vince Schaller, Managing Director, Schawk (Los Angeles)
“Ask your doctor if it’s right for you.” That advice, familiar in the U.S. ever since direct-to-consumer pharmaceutical advertising became legal nearly 20 years ago, is still sound. But today, consumers are increasingly asking themselves, before they even schedule a doctor’s appointment, “What are the right choices for me?”
Call it the increasing consumerism of health and wellness. Or, in the words of Kristin Hambelton, one of many CMOs who are bringing traditional marketing strategies to healthcare-oriented enterprises, call it the “Amazon Effect.” As...
Source: Mass Device - February 2, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog Schawk Source Type: news
ANA: Fingolimod Modulates RAGE in MS (CME/CE)
(MedPage Today) -- Pro-inflammatory markers in the serum reduced as anti-inflammatory molecules increase (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - October 19, 2016 Category: Radiology Source Type: news
